Entity

Time filter

Source Type

Austin, TX, United States

Luminex Software, Inc. is a developer and provider of disk-based mainframe virtual tape products and technologies for backup, archive and disaster recovery. Wikipedia.


News Article | October 29, 2015
Site: www.wsj.com

BOSTON—The most exclusive new club on Wall Street opens for business next week and there are a few things you won’t find: members with under a billion dollars or high-frequency traders. Those are among the rules laid out by the founding members of Luminex, a private trading platform designed to give the world’s largest asset managers a new place to buy and sell large blocks of stock.


News Article | October 28, 2015
Site: www.businesswire.com

SANTA CLARA, Calif.--(BUSINESS WIRE)--Affymetrix, Inc., (NASDAQ:AFFX) today reported its operating results for the third quarter of 2015. Results for the three months ended September 30, 2015: Product revenue for the third quarter of 2015 was $80.0 million and service and other revenue was $6.5 million. This compares to product revenue of $78.1 million and service and other revenue of $9.0 million in the third quarter of 2014. Product revenue for the third quarter of 2015 included consumable revenue of $75.7 million and instrument revenue of $4.3 million. Product revenue for the third quarter of 2014 included consumable revenue of $73.7 million and instrument revenue of $4.4 million. Total GAAP gross margin was 64%, as compared to 59% in the same period of 2014. Excluding non-GAAP adjustments such as the amortization of acquired intangible assets, non-GAAP gross margin for the third quarter of 2015 was 65% compared to 61% in the same period of 2014. This improvement was driven by higher sales as well as favorable manufacturing variances in the quarter. Please refer to the "Itemized Reconciliation Between GAAP and Non-GAAP Gross Margin" for a reconciliation of these GAAP and non-GAAP financial measures. For the third quarter of 2015, operating expenses were $59.5 million on a GAAP basis as compared to $46.6 million in the same period of 2014. GAAP operating expenses included $10.0 million of litigation settlement. Excluding non-GAAP adjustments, such as litigation costs and the amortization of acquired intangible assets, non-GAAP operating expenses for the third quarter of 2015 were $47.4 million, compared to an adjusted total of $44.1 million in the same period of 2014. The increase was primarily caused by higher headcount and associated compensation. Please refer to the "Itemized Reconciliation Between GAAP and Non-GAAP Operating Expenses" for a reconciliation of these GAAP and non-GAAP financial measures. “We generated strong growth in our clinical and eBioscience businesses in Q3 which grew by more than 30% and 11% respectively, the strongest organic growth for eBioscience since we completed the acquisition more than three years ago,” stated Frank Witney, President and CEO. “We reiterate our FY15 guidance for mid-single digit revenue growth. As a result of our strong gross margin and continued cost controls, we are raising our adjusted EBITDA guidance to 18-20% for 2015.” Affymetrix will host a conference call on Wednesday, October 28, 2015 at 2:00 p.m. PT to review its operating results for the third quarter of 2015. A live webcast can be accessed by visiting the Investor Relations section of the Company's website at www.affymetrix.com. In addition, investors and other interested parties can listen by dialing domestic: (877) 407-8291, international: (201) 689-8345. A replay of this call will be available from 5:00 p.m. PT on October 28, 2015 until 8:00 p.m. PT on November 4, 2015 at the following numbers: domestic: (877) 660-6853, international: (201) 612-7415. The conference call passcode to access the replay is 13621453. An archived webcast of the conference call will be available under the Investor Relations section of the Company's website. Affymetrix technology is used by the world's top pharmaceutical, diagnostic and biotechnology companies, as well as leading academic, government and nonprofit research institutes. More than 2,300 systems have been shipped around the world and more than 94,500 peer-reviewed papers have been published using the technology. Affymetrix is headquartered in Santa Clara, California, and has manufacturing facilities in Cleveland, Ohio, San Diego, California, Singapore and Vienna, Austria. The Company has about 1,200 employees worldwide and maintains sales and distribution operations across Europe, Asia and Latin America. All statements in this press release that are not historical in nature, are predicative in nature or that depend upon or refer to future events or conditions are "forward-looking statements" within the meaning of Section 21 of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These include statements regarding our strategic initiatives, market expectations, integration of and synergies related to eBioscience, anticipated product and revenue growth, financial strength and regulatory environment, as well as all other "expectations," "beliefs," "hopes," "intentions," "strategies" and words of similar import and the negatives thereof. Such statements are based on our current expectations and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. We cannot assure you that actual results or business conditions will not differ materially from those projected or suggested in such forward-looking statements as a result of various factors, including, but not limited to, those discussed in “Risk Factors” contained in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2014. These forward-looking statements speak only as of the date of the press release. Unless required by law, we do not undertake to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. In addition to providing financial measures based on generally accepted accounting principles in the United States (GAAP), Affymetrix has disclosed in this press release its net income (loss) and net income (loss) per share as well as its total gross margin and operating expenses for the third quarter of 2015 and 2014 excluding specified items. Reconciliation of GAAP to Non-GAAP measures can be found in the tables included in this press release. Affymetrix has determined to disclose this financial information to investors because it believes it will be useful, as a supplement to GAAP measures, in comparing Affymetrix's operating performance in the third quarter of 2015 as compared to the prior-year period. These Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information prepared in accordance with GAAP. Our management uses our supplemental non-GAAP financial measures internally to understand, manage and evaluate our business and make operating decisions. These non-GAAP measures are among the primary factors management uses in planning for and forecasting future periods. Affymetrix, the Affymetrix logo, GeneChip, and all other trademarks are the property of Affymetrix, Inc.


News Article | October 28, 2015
Site: www.businesswire.com

SANTA CLARA, Calif.--(BUSINESS WIRE)--Affymetrix, Inc., (NASDAQ:AFFX) today reported its operating results for the third quarter of 2015. Results for the three months ended September 30, 2015: Product revenue for the third quarter of 2015 was $80.0 million and service and other revenue was $6.5 million. This compares to product revenue of $78.1 million and service and other revenue of $9.0 million in the third quarter of 2014. Product revenue for the third quarter of 2015 included consumable revenue of $75.7 million and instrument revenue of $4.3 million. Product revenue for the third quarter of 2014 included consumable revenue of $73.7 million and instrument revenue of $4.4 million. Total GAAP gross margin was 64%, as compared to 59% in the same period of 2014. Excluding non-GAAP adjustments such as the amortization of acquired intangible assets, non-GAAP gross margin for the third quarter of 2015 was 65% compared to 61% in the same period of 2014. This improvement was driven by higher sales as well as favorable manufacturing variances in the quarter. Please refer to the "Itemized Reconciliation Between GAAP and Non-GAAP Gross Margin" for a reconciliation of these GAAP and non-GAAP financial measures. For the third quarter of 2015, operating expenses were $59.5 million on a GAAP basis as compared to $46.6 million in the same period of 2014. GAAP operating expenses included $10.0 million of litigation settlement. Excluding non-GAAP adjustments, such as litigation costs and the amortization of acquired intangible assets, non-GAAP operating expenses for the third quarter of 2015 were $47.4 million, compared to an adjusted total of $44.1 million in the same period of 2014. The increase was primarily caused by higher headcount and associated compensation. Please refer to the "Itemized Reconciliation Between GAAP and Non-GAAP Operating Expenses" for a reconciliation of these GAAP and non-GAAP financial measures. “We generated strong growth in our clinical and eBioscience businesses in Q3 which grew by more than 30% and 11% respectively, the strongest organic growth for eBioscience since we completed the acquisition more than three years ago,” stated Frank Witney, President and CEO. “We reiterate our FY15 guidance for mid-single digit revenue growth. As a result of our strong gross margin and continued cost controls, we are raising our adjusted EBITDA guidance to 18-20% for 2015.” Affymetrix will host a conference call on Wednesday, October 28, 2015 at 2:00 p.m. PT to review its operating results for the third quarter of 2015. A live webcast can be accessed by visiting the Investor Relations section of the Company's website at www.affymetrix.com. In addition, investors and other interested parties can listen by dialing domestic: (877) 407-8291, international: (201) 689-8345. A replay of this call will be available from 5:00 p.m. PT on October 28, 2015 until 8:00 p.m. PT on November 4, 2015 at the following numbers: domestic: (877) 660-6853, international: (201) 612-7415. The conference call passcode to access the replay is 13621453. An archived webcast of the conference call will be available under the Investor Relations section of the Company's website. Affymetrix technology is used by the world's top pharmaceutical, diagnostic and biotechnology companies, as well as leading academic, government and nonprofit research institutes. More than 2,300 systems have been shipped around the world and more than 94,500 peer-reviewed papers have been published using the technology. Affymetrix is headquartered in Santa Clara, California, and has manufacturing facilities in Cleveland, Ohio, San Diego, California, Singapore and Vienna, Austria. The Company has about 1,200 employees worldwide and maintains sales and distribution operations across Europe, Asia and Latin America. All statements in this press release that are not historical in nature, are predicative in nature or that depend upon or refer to future events or conditions are "forward-looking statements" within the meaning of Section 21 of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These include statements regarding our strategic initiatives, market expectations, integration of and synergies related to eBioscience, anticipated product and revenue growth, financial strength and regulatory environment, as well as all other "expectations," "beliefs," "hopes," "intentions," "strategies" and words of similar import and the negatives thereof. Such statements are based on our current expectations and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. We cannot assure you that actual results or business conditions will not differ materially from those projected or suggested in such forward-looking statements as a result of various factors, including, but not limited to, those discussed in “Risk Factors” contained in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2014. These forward-looking statements speak only as of the date of the press release. Unless required by law, we do not undertake to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. In addition to providing financial measures based on generally accepted accounting principles in the United States (GAAP), Affymetrix has disclosed in this press release its net income (loss) and net income (loss) per share as well as its total gross margin and operating expenses for the third quarter of 2015 and 2014 excluding specified items. Reconciliation of GAAP to Non-GAAP measures can be found in the tables included in this press release. Affymetrix has determined to disclose this financial information to investors because it believes it will be useful, as a supplement to GAAP measures, in comparing Affymetrix's operating performance in the third quarter of 2015 as compared to the prior-year period. These Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information prepared in accordance with GAAP. Our management uses our supplemental non-GAAP financial measures internally to understand, manage and evaluate our business and make operating decisions. These non-GAAP measures are among the primary factors management uses in planning for and forecasting future periods. Affymetrix, the Affymetrix logo, GeneChip, and all other trademarks are the property of Affymetrix, Inc.


News Article | January 3, 2014
Site: www.xconomy.com

To paraphrase the self-help saying, the first step in curing a problem is knowing that you have it. And Austin’s Luminex (Nasdaq: LMNX), with the help of its R&D team in Madison, WI, says it has found a way to help clinicians and researchers diagnose disease faster and more efficiently by enabling them to look for numerous diseases in a single sample. Instead of needing multiple samples for use in multiple tests to screen for a variety of pathogens—which requires the physician to know what to look for upfront—Luminex says its technology allows for broad screening to be done at the same time. For example, with traditional tests, a clinician would test for one strain of the flu. If that test came up negative, the caregiver would have to set up additional tests until a culprit could be found. For such respiratory viruses, Luminex can test for up to 80 percent of the pathogens that could be responsible for such illness in a single sample, says Russell Bradley, Luminex’s senior VP for marketing and business development. More broadly, the company can test for up to 500 different pathogens, he added. “That’s our claim to fame with health care wanting to do more with less,” he says. “We require less samples, less tests, faster testing.” Luminex’s fundamental concept is carried out by an instrument called xMap. The technology uses a reader that examines microscopic “beads,” which are themselves tagged for specific pathogens. The beads are coated with the sample and the instrument then identifies which of those beads have found their targets. The company, which was founded in 1995 and went public five years later, currently sells four types of instruments. About 10,000 are used in the marketplace today, Bradley says. Luminex’s customers include medical institutions, academic medical centers, and labs that do testing for clinical patient samples. A few other companies—Hologic in Bedford, MA, Roche Diagnostics, and Cepheid in Sunnyvale, CA—provide similar testing products, but Bradley says their competitors don’t have the same diagnostic scale as Luminex. Over the years, Luminex has expanded out of its home in the Texas capital. In 2006, it purchased Toronto-based TM Biosciences, which produces tests for infectious diseases as well as genetic disorders such as cystic fibrosis. Two years ago, it bought what was then called EraGen BioScience, for $34 million. The Madison, WI, company had been founded in 1999 and it develops molecular reagent assays, or testing, kits. The two companies had already formed an official partnership in 2005, when the Madison company licensed Luminex’s device for its assays. So, when it came to expanding its chemistry portfolio, Bradley says, Luminex turned to EraGen. “We were really excited about their chemistry technology, which was very complementary to what we are trying to do in diagnostics,” he says. “That, and the talent they had in the team up there, we saw it as a way of accelerating our own programs.” Beyond the existing business relationship, he adds that EraGen’s presence in Wisconsin was equally important. “I can remember distinctly when we were profiling EraGen, we liked the fact that it was based in Madison,” Bradley says. “It has a fairly dynamic biotech environment, and it gives us a chance to attract and retain the biotech talent we wanted to continue to invest in.” In fact, Bradley says that Madison’s biotech ecosystem helps fill some gaps he sees in the Austin biotech community, which he describes as still being “embryonic.” “We believe when Austin gets a medical school and can attract some research funding to Austin, that will be a catalyst for a lot of biotech in Austin,” he says. “It’s primed for growth.” The company today has 700 employees, including 40 in Madison. Russell says he expects that group to grow larger as Luminex expands its operations there. “We actually just moved from the EraGen facility to a new bigger facility close by,” he says. Angela Shah is the editor of Xconomy Texas. She can be reached at ashah@xconomy.com or (214) 793-5763. Follow @angelashah


NEW YORK--(BUSINESS WIRE)--Enzo Biochem, Inc. (NYSE:ENZ) today announced that it has reached and finalized a settlement with Luminex Corporation (NASDAQ:LMNX) involving payment of $7.1 million to Enzo in an infringement action brought by Enzo regarding its U.S. Patents Nos. 6,992,180; 7,064,197; and 8,097,405. Today’s settlement resolving the disputes between Enzo and Luminex impacts only one of 12 cases originally brought by Enzo in the United States District Court for the District of Delaware alleging patent infringements against various companies, the remainder of which are still pending. Enzo Biochem is a pioneer in molecular diagnostics, leading the convergence of clinical laboratories, life sciences and therapeutics through the development of unique diagnostic platform technologies that provide numerous advantages over previous standards. A global company, Enzo Biochem utilizes cross-functional teams to develop and deploy products systems and services that meet the ever-changing and rapidly growing needs of health care both today and into the future. Underpinning Enzo Biochem’s products and technologies is a broad and deep intellectual property portfolio, with patent coverage across a number of key enabling technologies. Except for historical information, the matters discussed in this news release may be considered "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements include declarations regarding the intent, belief or current expectations of the Company and its management, including those related to cash flow, gross margins, revenues, and expenses are dependent on a number of factors outside of the control of the company including, inter alia, the markets for the Company’s products and services, costs of goods and services, other expenses, government regulations, litigations, and general business conditions. See Risk Factors in the Company’s Form 10-K for the fiscal year ended July 31, 2014. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that could materially affect actual results. The Company disclaims any obligations to update any forward-looking statement as a result of developments occurring after the date of this press release.

Discover hidden collaborations